[go: up one dir, main page]

WO2015021704A1 - Utilisations de doxycycline pour préparer des médicaments antitumoraux - Google Patents

Utilisations de doxycycline pour préparer des médicaments antitumoraux Download PDF

Info

Publication number
WO2015021704A1
WO2015021704A1 PCT/CN2013/087571 CN2013087571W WO2015021704A1 WO 2015021704 A1 WO2015021704 A1 WO 2015021704A1 CN 2013087571 W CN2013087571 W CN 2013087571W WO 2015021704 A1 WO2015021704 A1 WO 2015021704A1
Authority
WO
WIPO (PCT)
Prior art keywords
doxycycline
tumor
cells
cancer
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2013/087571
Other languages
English (en)
Chinese (zh)
Inventor
饶子和
孙涛
杨诚
周红刚
郭宇
刘慧娟
刘艳荣
王静
张博
李珊
翟佳黛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TIANJIN INTERNATIONAL JOINT ACADEMY OF BIOTECHNOLOGY AND MEDICINE
TIANJIN INTERNATIONAL JOINT ACADEMY OF BIOTECHNOLOGY AND MEDICINE Co Ltd
XUHE (TIANJIN) YIYAOKEJIYOUXIANGONGSI
Original Assignee
TIANJIN INTERNATIONAL JOINT ACADEMY OF BIOTECHNOLOGY AND MEDICINE
TIANJIN INTERNATIONAL JOINT ACADEMY OF BIOTECHNOLOGY AND MEDICINE Co Ltd
XUHE (TIANJIN) YIYAOKEJIYOUXIANGONGSI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TIANJIN INTERNATIONAL JOINT ACADEMY OF BIOTECHNOLOGY AND MEDICINE, TIANJIN INTERNATIONAL JOINT ACADEMY OF BIOTECHNOLOGY AND MEDICINE Co Ltd, XUHE (TIANJIN) YIYAOKEJIYOUXIANGONGSI filed Critical TIANJIN INTERNATIONAL JOINT ACADEMY OF BIOTECHNOLOGY AND MEDICINE
Publication of WO2015021704A1 publication Critical patent/WO2015021704A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Definitions

  • the present invention relates to the field of medicinal chemistry and, in particular, to the use of doxycycline for the preparation of antineoplastic agents. Background technique
  • Doxycycline (also known as doxycycline), a tetracycline antibiotic, is a well-known and widely used antibiotic. Tetracyclines mainly act on the 30S subunit of the bacterial ribosome, interfering with the amino acid tRNA binding to the site of action on the 30S subunit, blocking the binding of the aminoacyl tRNA to the ribosome-mRNA complex, inhibiting protein synthesis, and also altering The permeability of the cell membrane exposes the nucleotides of important substances in the cell, inhibits DNA synthesis, and thus achieves an antibacterial effect.
  • Doxycycline is a potent and widely used type of tetracycline (Adimora AA., 2002; Kovacova E, et al., 2002). About doxycycline is currently used clinically for the treatment of upper respiratory tract infections, biliary tract infections, urinary tract infections, chronic bronchitis, acute and chronic bronchitis, pneumonia, bronchitis, cellulitis and other symptoms.
  • malignant tumors such as liver cancer, breast cancer, lung cancer, pancreatic cancer, colon cancer, and melanoma
  • Malignant tumors such as liver cancer, breast cancer, lung cancer, pancreatic cancer, colon cancer, and melanoma are high-risk diseases. Because these malignant tumors generally have the ability to metastasize and invade, it is difficult to cure once the above diseases occur, which may cause human health.
  • Existing anti-tumor drugs against liver cancer, breast cancer, lung cancer, pancreatic cancer, colon cancer, melanoma and other malignant tumors are not only low in anti-tumor activity, but also expensive, and patients are often unbearable, and even some patients cannot afford expensive prices. And gave up the treatment opportunity. Therefore, there is an urgent need to develop new anti-tumor growth, metastasis or invasion drugs. Summary of the invention
  • the object of the present invention is to provide an application of doxycycline in the preparation of an antitumor drug.
  • the present invention provides the use of doxycycline for the preparation of an antitumor drug, wherein the doxycycline
  • the tumor involved comprises: breast cancer, liver cancer, melanoma, lung cancer, pancreatic cancer, colon or a combination thereof.
  • antitumor drugs including as a cytotoxic drug in the inhibition of tumor growth, as a drug against tumor metastasis, or as a drug against tumor invasion Applications.
  • the anti-tumor agent comprises a therapeutically effective amount of doxycycline, or a pharmaceutically acceptable salt, or ester thereof, and an adjuvant.
  • the effective therapeutic amount of the antitumor drug is from 100 m g / k g to 300 mg / kg.
  • the antitumor drug is selected from the group consisting of a tablet, a capsule, a pill, a liquid preparation, a granule, a powder, an injection, or a combination thereof.
  • the administration of the antitumor drug includes oral administration, injection, implantation, external application, spraying, inhalation, or a combination thereof.
  • the anti-tumor drug provided by the present invention has the advantage that the patient is easy to accept and easy to understand the patient's response to the drug, is inexpensive, and is easily available.
  • doxycycline will change the market pattern of existing cancer chemotherapy drugs, becoming a clinical drug that can be taken for a long time and effectively inhibits tumor metastasis, invasion and recurrence.
  • the doxycycline used in the present invention is doxycycline hydrochloride, which was purchased from Shanghai Shengong (production batch number DB0889-25g).
  • the chemical structural formula of doxycycline hydrochloride is: DRAWINGS
  • Figure 1 shows the inhibitory effect of cetcycline on the human breast cancer cell line MCF-7
  • Figure 2 shows the inhibitory effect of '''xicycline on the human hepatoma cell line HepG-2;
  • Figure 3 shows the inhibitory effect of cetcycline-doxcycline on mouse melanoma B-16 cells.
  • Figure 4 shows the inhibitory effect of ''sicycline on human small cell lung cancer cell NCI-H446;
  • Figure 5 shows the inhibitory effect of '''xicycline on pancreatic cancer cell line PC-3;
  • Figure 6 shows the inhibitory effect of '''xicycline on human colon cancer cell LOVO
  • Figure 7 shows the effect of '''xicycline on migration of MCF-7 cells
  • Figure 8 shows the effect of cycline on the migration of HepG2 cells
  • Figure 9 shows the effect of cyclulin on the migration of B16 cells
  • Figure 10 shows the effect of %ccycline on migration of human small cell lung cancer cells NCI-H446;
  • Figure 11 shows the effect of cilin on the migration of pancreatic cancer cell line PC-3;
  • Figure 12 shows the effect of %ccycline on LOVO migration in human colon cancer cells
  • Figure 13 shows the inhibitory effect of cyclulin on the tumor size of tumor-bearing mice
  • Figure 14 shows the effect of cyclulin on the tumor growth state of tumor-bearing mice.
  • the inventors have confirmed, through extensive experimental studies, the antitumor activity of tetracycline-structured doxycycline.
  • the specific embodiment is as follows.
  • test materials used and their sources include: Doxycycline hydrochloride, purchased from Shanghai Shengong (production batch number: DB0889-25g); high sugar DMEM medium, RIPM 1640 medium, fetal bovine serum FBS (Hy clone brand) purchased from Thermo company; Thiazole blue (MTT) was purchased from Sigma, USA; 96-well plate (Nunc brand) was purchased from Thermo; Hochest 33342 was purchased from Biyuntian Biotechnology Co., Ltd.; DMSO was purchased from Sigma, USA; C57/BL mice were purchased from Shanghai Lake Laboratory Animals Ltd.
  • Example 1 Inhibition of doxycycline on the growth of different tumor cells
  • Doxycycline was formulated into 30 mM mother liquor in DMSO and stored. The medium was diluted with the culture solution to the use concentration.
  • the cell line was selected as: human breast cancer cell line MCF-7 (medium: RIPM 1640 plus 10% FBS, purchased from Beijing Jin Zijing Biomedical Technology Co., Ltd.); human hepatoma cell line HepG-2 (medium: DMEM high) Sugar medium plus 10% FBS, purchased from Beijing Jin Zijing Biomedical Technology Co., Ltd.); mouse melanoma B-16 cells (medium: RIPM 1640 plus 10% FBS, purchased from Beijing Jin Zijing Biomedical Technology Co., Ltd.); Human small cell lung cancer cell NCI-H446 (medium: RIPM 1640 plus 10% FBS, purchased from Nanjing Kaiji Biotechnology Development Co., Ltd.); Pancreatic cancer cell PC-3 (medium: RIPM 1640 plus 10% FBS, Purchased from Nanjing Kaiji Biotechnology Development Co., Ltd.); human colon cancer cell LOVO (medium: RIPM 1640 plus 10% FBS, purchased from Nanjing Kaiji Biotechnology Development Co., Ltd.).
  • the experimental method is MTT colorimetry: the detection principle is that succinate dehydrogenase in living cell mitochondria can reduce exogenous MTT to water-insoluble blue-violet crystal sputum (Formazan) and deposit in cells, while dead cells have no this function.
  • Dimercaptosulfoxide (DMSO) is capable of lysing sputum in cells, and its absorbance is measured at 490 nm by an enzyme-linked immunosorbent assay, which indirectly reflects the number of viable cells. Within a certain number of cells, the amount of strontium crystal formation is proportional to the number of cells. This method has been widely used for the detection of activity of some biologically active factors, large-scale anti-tumor drug screening, cytotoxicity tests, and tumor radiosensitivity assays.
  • the specific experimental steps are as follows: After the cells are trypsinized, the cells are dispersed into individual cells and suspended in the corresponding medium. The cells were seeded on 96-well plates at 4000 cells/well. The cells were cultured overnight in a 37 ° C carbon dioxide (5%) incubator to allow the cells to adhere. The next day, discard the culture solution and add a cell culture medium containing a series of doxycycline concentrations (specific concentrations in each cell) The results are described in the results) and control wells without drug concentration were set. After incubating for 48 hours in a 37 ° C carbon dioxide ( 5 % ) incubator, 20 ⁇ M TT mother liquor (5 mg/mL mother liquor concentration) was added to each well and incubation was continued for 4 h.
  • the culture solution was aspirated, 150 ⁇ l of DMSO was added to each well as a solvent to dissolve hydrazine, and after dissolution, the absorbance at 490 nm was measured with a microplate reader (Multiscan FC, Thermo company), and the cell survival rate was calculated by the following formula:
  • the dose response curve of doxycycline on the cytotoxicity of human breast cancer cell line MCF-7 is shown in Figure 1.
  • the concentrations of doxycycline used were: 0 ⁇ , 0.39063 ⁇ , 0.78125 ⁇ , 1.5625 ⁇ , 3.125 ⁇ , 6.25 ⁇ , 12.5 ⁇ , 25 ⁇ , 50 ⁇ , 100 ⁇ . It can be seen from Figure 1 that the survival rate of MCF-7 cells is 20% at 100 ⁇ .
  • the inhibition of proliferation of MCF-7 cells by doxycycline reached 80%. It indicated that doxycycline had a good inhibitory effect on the proliferation of MCF-7 cells.
  • the dose response curve of cytotoxicity of doxycycline on human hepatoma cell line HepG-2 is shown in Figure 2.
  • the concentrations of the drugs used were: 0 ⁇ , 0.39063 ⁇ , 0.78125 ⁇ , 1.5625 ⁇ , 3.125 ⁇ , 6.25 ⁇ , 12.5 ⁇ , 25 ⁇ , 50 ⁇ , 100 ⁇ .
  • the survival rate of HepG-2 cells was 80% when the concentration of doxycycline was 100 ⁇ .
  • the inhibitory effect of doxycycline on HepG-2 cell proliferation was 20%. It indicated that doxycycline had a certain inhibitory effect on the proliferation of HepG-2 cells.
  • the results of doxycycline on mouse melanoma B-16 cytotoxicity test are shown in Figure 3.
  • the concentrations of the drugs used were: 0 ⁇ , 0.78 ⁇ , 1.56 ⁇ , 3.125 ⁇ , 12.5 ⁇ , 25 ⁇ , 50 ⁇ , 100 ⁇ .
  • the cell survival rate was 0.04% at a drug concentration of 100 ⁇ .
  • the inhibitory rate of doxycycline on B-16 cell proliferation was 99.6%. This indicates that doxycycline has a very good inhibitory effect on the proliferation of B-16 cells.
  • the test results of doxycycline on human small cell lung cancer cells NCI-H446 are shown in Fig. 4.
  • the concentrations of doxycycline used were: 0 ⁇ , 0.78 ⁇ , 1.5625 ⁇ , 3.125 ⁇ , 6.25 ⁇ , 12.5 ⁇ , 25 ⁇ , 50 ⁇ , 100 ⁇ , 200 ⁇ .
  • the cell survival rate was 29% at a drug concentration of 200 ⁇ .
  • the inhibition rate of doxycycline on the proliferation of human small cell lung cancer cell line NCI-H446 reached 71%. It indicated that doxycycline had a good inhibitory effect on the proliferation of human small cell lung cancer cell line NCI-H446.
  • the toxicity test results of doxycycline on human pancreatic cancer cell line PC-3 are shown in Fig. 5.
  • the drug concentrations used were: 0 ⁇ , 1.563 ⁇ , 3.125 ⁇ , 6.25 ⁇ , 12.5 ⁇ , 25 ⁇ , 100 ⁇ , 200 ⁇ .
  • the cell survival rate was 74% at a drug concentration of 200 ⁇ .
  • the inhibition rate of doxycycline on the proliferation of human pancreatic cancer cell line PC-3 reached 26%. This indicates that doxycycline has a certain inhibitory effect on the proliferation of human pancreatic cancer cell line PC-3.
  • the toxicity test results of doxycycline on human colon cancer cell LOVO are shown in Figure 7.
  • the concentrations of the drugs used were: 0 ⁇ , 0.781 ⁇ , 1.563 ⁇ , 3.125 ⁇ , 6.25 ⁇ , 12.5 ⁇ , 25 ⁇ , 100 ⁇ , 200 ⁇ .
  • the cell survival rate was 79% at a drug concentration of 200 ⁇ .
  • the inhibition rate of doxycycline on LOVO proliferation in human colon cancer cells reached 21%. It indicates that doxycycline has a certain inhibitory effect on the proliferation of human colon cancer fine LOVO.
  • Example 2 In vitro cell level detection of the effect of doxycycline on cell migration
  • the cells are dispersed into individual cells and suspended in the corresponding medium.
  • the cells were seeded on 96-well plates at 4000 cells/well.
  • the cells were cultured overnight in a 37 ° (carbon dioxide (5%) incubator.
  • the culture solution was discarded and a medium containing a series of concentrations of the test substance (doxycycline) was added.
  • the staining solution is 50 ⁇ ! 7 well, 37 ° C carbon dioxide (5%) Incubate for 20 min in the incubator.
  • the effect of doxycycline on cells can be divided by the software that comes with the high content analysis platform. Analysis.
  • the effect of the drug on cell migration rate is primarily indicated by the slope of the curve in the resulting average distance-time plot. The higher the slope, the faster the cell migration rate, and the smaller the slope, the slower the cell migration rate.
  • the inhibitory effect of doxycycline on MCF-7 cell migration is shown in Figure 7.
  • D7 is the control group
  • D8 and D9 are the dosing group
  • the D8 group has a drug concentration of 20 ⁇
  • the D9 group has a drug concentration of 4 ⁇ .
  • the slope of the motion curve of the cells in the dosing group was significantly smaller than that of the control group. It was proved that doxycycline significantly inhibited the migration of MCF-7 cells.
  • the inhibitory effect of doxycycline on HepG-2 cell migration is shown in Figure 8.
  • C6 is the control group
  • C7 and C8 are the doxycycline group
  • the C7 and C8 groups are all 20 ⁇ . It can be seen from the figure that the slope of the motion curve of the cells in the dosing group is significantly smaller than that of the control group. It was demonstrated that doxycycline inhibited the migration of HepG-2 cells.
  • the inhibitory effect of doxycycline on B16 cell migration is shown in Figure 9.
  • B6 is the control group
  • B7 and B8 are the forces.
  • the drug concentration in the B7 group was 4 ⁇
  • the drug concentration in the ⁇ 8 group was 20 ⁇ .
  • the slope of the motion curve of the cells in the dosing group was significantly smaller than that of the control group. It was demonstrated that doxycycline significantly inhibited the migration of B16 cells.
  • the inhibitory effect of doxycycline on NCI-H446 cell migration is shown in Figure 10.
  • D11 is the control group
  • D9 and D10 are the dosing group
  • the D9 group has a drug concentration of 4 ⁇
  • the D10 group has a drug concentration of 20 ⁇ .
  • the slope of the motion curve of the cells in the dosing group was significantly smaller than that of the control group. It was proved that doxycycline significantly inhibited the migration of NCI-H446 cells.
  • the inhibitory effect of doxycycline on PC-3 cell migration is shown in Figure 11.
  • C2 is the control group
  • C3, C4, and C5 are the dosing group
  • the drug concentration is 20 ⁇ .
  • the slope of the motion curve of the cells in the dosing group was smaller than that of the control group. It was proved that doxycycline has a certain inhibitory effect on the migration of PC-3 cells.
  • mice Experimental method for establishing a tumor-bearing model in mice:
  • B-16 cell suspension After trypsinization, the cells were centrifuged at 800 rpm, the cells were resuspended in PBS, centrifuged again, and the remaining medium was washed away. After the cells were counted, the cells were made into a cell suspension of lx10 7 cells/mL.
  • the mouse tumor is allowed to grow until it is ready to be administered.
  • mice make doxycycline into 10 mg/ml with normal saline.
  • One group of mice was used as an experimental group, and doxycycline was intraperitoneally administered, and each mouse was administered with 50 mg/kg.
  • Another group of mice was used as a control group, and normal saline was intraperitoneally injected as a control.
  • the daily administration was performed, and the volume of the tumor of the administration group and the control group was measured every day. Six days after the administration, the mice were sacrificed, and tumor tissues were taken for sectioning for histomorphometric analysis.
  • the inhibitory effect of doxycycline on tumor size in tumor-bearing mice is shown in Figure 13 (C: control group, no administration, only saline; DOX: doxycycline administration group), doxycycline
  • C control group, no administration, only saline
  • DOX doxycycline administration group
  • the tumor volume of the mice in the drug group was significantly smaller than that in the control group, and the tumor volume of the mice in the doxycycline group was relatively uniform, which showed that doxycycline had a good inhibitory effect on the growth of mouse melanoma.
  • doxycycline The effect of doxycycline on tumor growth status in tumor-bearing mice is shown in Figure 14 (C: control group, no administration, only saline; DOX: doxycycline administration group): The blood vessels are rich, the peritoneum is invaded, and the necrosis is less. The doxycycline-administered group has small tumor volume, few blood vessels, easy to peel off the invading peritoneum, and a large amount of necrosis in the middle. Doxycycline administration compared to the control group The tumor metastasis of the group was not obvious. It is shown that doxycycline has a certain ability to resist tumor metastasis.
  • Example 1 it can be seen from Example 1 that when the concentration of doxycycline is 100 ⁇ , the inhibition rate of doxycycline on MCF-7 cell proliferation is 80%, and the inhibition rate on HepG-2 cell proliferation is 20%. The inhibition rate of B-16 cell proliferation reached 99.6%.
  • doxycycline concentration was 200 ⁇ , doxycycline inhibited the proliferation of human small cell lung cancer cell line NCI-H446 by 71% and inhibited the proliferation of human pancreatic cancer cell line PC-3 by 26%.
  • the inhibition rate of LOVO proliferation in human colon cancer cells reached 21%.
  • Example 2 It can be seen from Example 2 that the slope of the movement curve of the cells in the drug-added group is smaller than that of the control group, and the migration of doxycycline to MCF-7 cells, HepG-2B16 cells, NCI-H446 cells, PC-3 cells, and LOVO cells was confirmed. There is a certain inhibition. This indicates that doxycycline has different inhibitory effects on the proliferation and migration of malignant tumor cells of breast cancer, liver cancer, melanoma, lung cancer, pancreatic cancer and colon cancer.
  • Example 3 It can be seen from Example 3 that the volume of d and mouse tumors in the doxycycline-administered group was smaller than that in the control group, and the tumor size of the d and the rats in the doxycycline-administered group was relatively uniform, and no malignant growth occurred; It was found that doxycycline can significantly inhibit tumor invasion of the peritoneum.
  • doxycycline in the preparation of antitumor drugs can be seen from the above experiments.
  • the doxycycline of the present invention has advantages unmatched by other drugs, and the patient is easy to accept and easy to understand the patient's response to the drug, and is inexpensive and easy to obtain.
  • doxycycline will change the market pattern of existing cancer chemotherapy drugs, and gradually become a clinical drug that can be taken for a long time and effectively inhibits tumor metastasis, invasion and recurrence.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des utilisations de doxycycline pour préparer des médicaments antitumoraux. Selon la présente invention, les activités antitumorales de la doxycycline comprennent principalement des effets d'inhibition de la croissance tumorale et des activités pour une résistance contre une métastase tumorale et une invasion tumorale. Au moyen d'expériences aux niveaux de la cellule et de l'animal in vitro, il est démontré que la doxycycline a des effets sur l'inhibition de la croissance et la métastase de tumeurs malignes, telles que le cancer du sein, le cancer du foie, le mélanome, le cancer du poumon, le cancer du pancréas et le cancer du côlon, et la doxycycline présente également de bons effets antitumoraux sur un modèle de souris atteinte de tumeur. De plus, la doxycycline de la présente invention a des avantages incomparables que d'autres médicaments n'ont pas, les patients sont plus disposés à recevoir un traitement, et les réactions des patients aux médicaments peuvent être obtenues de façon commode. La doxycycline changera la configuration du marché des médicaments de chimiothérapie antitumorale existants, et deviendra un médicament clinique qui pourra être utilisé pendant longtemps et pourra inhiber efficacement une métastase, une invasion et une récurrence de tumeurs.
PCT/CN2013/087571 2013-08-13 2013-11-21 Utilisations de doxycycline pour préparer des médicaments antitumoraux Ceased WO2015021704A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310352767.6A CN104367584A (zh) 2013-08-13 2013-08-13 多西环素在制备抗肿瘤药物中的应用
CN201310352767.6 2013-08-13

Publications (1)

Publication Number Publication Date
WO2015021704A1 true WO2015021704A1 (fr) 2015-02-19

Family

ID=52467977

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2013/087571 Ceased WO2015021704A1 (fr) 2013-08-13 2013-11-21 Utilisations de doxycycline pour préparer des médicaments antitumoraux
PCT/CN2014/000721 Ceased WO2015021741A1 (fr) 2013-08-13 2014-07-29 Utilisation de doxycycline

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/CN2014/000721 Ceased WO2015021741A1 (fr) 2013-08-13 2014-07-29 Utilisation de doxycycline

Country Status (2)

Country Link
CN (1) CN104367584A (fr)
WO (2) WO2015021704A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4426304A4 (fr) * 2021-11-02 2025-11-26 Verastem Inc Méthodes de traitement de croissance cellulaire anormale

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106551944A (zh) * 2015-09-25 2017-04-05 南开大学 四环素类衍生物作为par-1抑制剂的用途
CN110960523B (zh) * 2018-09-30 2022-11-22 中南大学湘雅医院 针对Fyn-CD147信号通路靶点的抗肿瘤化合物的应用及抗肿瘤药物
CN109568327A (zh) * 2019-01-10 2019-04-05 天津国际生物医药联合研究院 多西环素在制备抗肿瘤药物中的应用
CN109662971A (zh) * 2019-01-30 2019-04-23 天津国际生物医药联合研究院 多西环素在制备髓源抑制性细胞的抑制性药物中的应用
GB201904851D0 (en) * 2019-04-05 2019-05-22 Katholieke Univ Leven Melanoma treatment
CN115006411A (zh) * 2022-07-26 2022-09-06 中南大学湘雅医院 依拉环素类化合物的应用、药物及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103006675A (zh) * 2012-11-19 2013-04-03 中国人民解放军第二军医大学 多西环素在制备治疗上皮性卵巢癌药物中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103006675A (zh) * 2012-11-19 2013-04-03 中国人民解放军第二军医大学 多西环素在制备治疗上皮性卵巢癌药物中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHI, YUNLONG: "Experimental Study of the Inhibition of Cell Proliferation and Metastases by Doxycycline in Human Colon Carcinoma", CHINESE DOCTORAL DISSERTATIONS & MASTER'S THESES FULL-TEXT DATABASE (MASTER) MEDICINE AND HEALTH SCIENCES, 15 December 2006 (2006-12-15) *
ZHANG, QIANGBO ET AL.: "Doxycycline Inhibits the Growth of Human Hepatoma Cell HepG2 in Vitro.", CHIN J CURR ADV GEN SURG., vol. 11, no. 2, 30 April 2008 (2008-04-30) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4426304A4 (fr) * 2021-11-02 2025-11-26 Verastem Inc Méthodes de traitement de croissance cellulaire anormale

Also Published As

Publication number Publication date
WO2015021741A1 (fr) 2015-02-19
CN104367584A (zh) 2015-02-25

Similar Documents

Publication Publication Date Title
WO2015021704A1 (fr) Utilisations de doxycycline pour préparer des médicaments antitumoraux
CN101429201A (zh) 柠檬酸小檗胺盐及制备方法和应用
CN102441168B (zh) 含芹菜素及芹菜素类衍生物和Bcl-2抑制剂的药物组合物及其在制备治疗癌症的药物中的应用
CN102688493B (zh) 含有白藜芦醇及白藜芦醇类衍生物和Bc1-2抑制剂的药物组合物及其应用
CN106692150B (zh) 尼达尼布在制备预防和治疗肝纤维化与肝硬化的药物中的用途
CN110327466B (zh) 用于治疗肝纤维化的药物组合物及其应用
CN119139278A (zh) 一种联苯环辛烯型木脂素类化合物的应用及化疗增敏药物
CN102688489A (zh) 含有雷公藤甲素及雷公藤甲素类衍生物和Bcl-2抑制剂的药物组合物及其应用
CN112494490B (zh) 匹莫范色林酒石酸盐在制备治疗胶质瘤药物中的应用
CN117442704A (zh) 一种治疗前列腺癌的药物组合及其应用
WO2023245847A1 (fr) Utilisation d'un composé à petites molécules d'acide borique dans la préparation de médicaments pour améliorer l'effet curatif d'un inhibiteur de point de contrôle immunitaire et traiter la leucémie
CN102688490B (zh) 含有吴茱萸碱及吴茱萸碱类衍生物和Bc1-2抑制剂的药物组合物及其应用
CN101757626B (zh) 含有胰岛素样生长因子-i受体抑制剂和组蛋白去乙酰化酶抑制剂的药物组合物及其应用
CN114569590A (zh) 新鱼腥草素钠的医药用途
CN101829077A (zh) 二咖啡酰奎尼酸衍生物在制备用于治疗支原体感染疾病药物中的用途
CN106551944A (zh) 四环素类衍生物作为par-1抑制剂的用途
CN107243079B (zh) 一种含大黄酸的药物组合物及其在制备抗肿瘤药物中的应用
CN105669666A (zh) 小分子化合物yf-452及其在制备抗血管新生药物中的应用
CN101653607A (zh) 含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途
CN119606963B (zh) 一种有效清除衰老肠细胞的药物及其在治疗肠道炎症病症中的应用
CN104095844A (zh) 牛蒡子苷元在制备治疗肝纤维化或肝硬化药物中的应用
KR20220008895A (ko) 섬유증을 예방, 완화 및/또는 치료하는 약물, 복합 제품 및 이의 응용
CN115317483A (zh) 氯喹及其衍生物在制备PGCCs抑制剂中的应用
CN108721280A (zh) 来氟米特和特立氟胺在白血病治疗中的应用
CN117205219A (zh) Notch抑制剂联合jak-stat抑制剂在治疗肝癌中的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13891380

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 30-05-2016)

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 30-05-2016)

122 Ep: pct application non-entry in european phase

Ref document number: 13891380

Country of ref document: EP

Kind code of ref document: A1